Prevalence of Micronutrient Deficiencies and Relationship with Clinical and Patient-Related Outcomes in Pulmonary Hypertension Types I and IV.
Aged
Chronic Disease
/ epidemiology
Cohort Studies
Female
Humans
Hypertension, Pulmonary
/ epidemiology
Iron Deficiencies
/ epidemiology
Male
Micronutrients
/ deficiency
Middle Aged
Nutritional Status
Patient Outcome Assessment
Prevalence
Prospective Studies
Pulmonary Arterial Hypertension
/ epidemiology
Vitamin D Deficiency
/ epidemiology
chronic thrombo-embolic pulmonary hypertension
iron
micronutrient deficiencies
pulmonary arterial hypertension
pulmonary hypertension
vitamin D
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
01 Nov 2021
01 Nov 2021
Historique:
received:
16
09
2021
revised:
15
10
2021
accepted:
21
10
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Pulmonary hypertension (PH) is a rare progressive and lethal disease affecting pulmonary arteries and heart function. The disease may compromise the nutritional status of the patient, which impairs their physical performance. This study aimed to determine the prevalence of micronutrient deficiencies in pulmonary arterial hypertension (PAH) and chronic thrombo-embolic pulmonary hypertension (CTEPH) patients. Eighty-one blood samples from a prospective observational cohort study were analyzed for concentrations of micronutrients and inflammation-related factors. The samples consisted of newly diagnosed (treatment-naive) PAH and CTEPH patients and patients treated for 1.5 years according to ERS/ESC guidelines. In the newly diagnosed group, 42% of PAH patients and 21% of CTEPH patients were iron deficient compared to 29% of PAH patients and 20% of CTEPH patients in the treatment group. Vitamin D deficiency occurred in 42% of the newly diagnosed PAH patients, 71% of the newly diagnosed CTEPH patients, 68% of the treated PAH patients, and 70% of the treated CTEPH patients. Iron levels correlated with the 6 min walking distance (6MWD). Iron and vitamin D deficiencies are highly prevalent in PAH and CTEPH patients, underlining the need for monitoring their status. Studies evaluating the effects of supplementation strategies for iron and vitamin D are necessary.
Sections du résumé
BACKGROUND
BACKGROUND
Pulmonary hypertension (PH) is a rare progressive and lethal disease affecting pulmonary arteries and heart function. The disease may compromise the nutritional status of the patient, which impairs their physical performance. This study aimed to determine the prevalence of micronutrient deficiencies in pulmonary arterial hypertension (PAH) and chronic thrombo-embolic pulmonary hypertension (CTEPH) patients.
METHODS
METHODS
Eighty-one blood samples from a prospective observational cohort study were analyzed for concentrations of micronutrients and inflammation-related factors. The samples consisted of newly diagnosed (treatment-naive) PAH and CTEPH patients and patients treated for 1.5 years according to ERS/ESC guidelines.
RESULTS
RESULTS
In the newly diagnosed group, 42% of PAH patients and 21% of CTEPH patients were iron deficient compared to 29% of PAH patients and 20% of CTEPH patients in the treatment group. Vitamin D deficiency occurred in 42% of the newly diagnosed PAH patients, 71% of the newly diagnosed CTEPH patients, 68% of the treated PAH patients, and 70% of the treated CTEPH patients. Iron levels correlated with the 6 min walking distance (6MWD).
CONCLUSIONS
CONCLUSIONS
Iron and vitamin D deficiencies are highly prevalent in PAH and CTEPH patients, underlining the need for monitoring their status. Studies evaluating the effects of supplementation strategies for iron and vitamin D are necessary.
Identifiants
pubmed: 34836178
pii: nu13113923
doi: 10.3390/nu13113923
pmc: PMC8617670
pii:
doi:
Substances chimiques
Micronutrients
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Actelion Pharmaceuticals
ID : N/A
Organisme : Actelion Pharmaceuticals
ID : N/A
Références
Caspian J Intern Med. 2016 Fall;7(4):253-259
pubmed: 27999642
Thorax. 2011 Apr;66(4):326-32
pubmed: 21297151
Scand Cardiovasc J. 2021 Feb;55(1):43-49
pubmed: 32586166
PLoS One. 2018 Aug 28;13(8):e0198650
pubmed: 30153256
Nutrients. 2018 Nov 03;10(11):
pubmed: 30400332
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545970
Am J Clin Nutr. 2007 Mar;85(3):755-61
pubmed: 17344497
Eur Respir J. 2011 Jun;37(6):1386-91
pubmed: 20884742
Scand Cardiovasc J. 2016 Aug;50(4):243-50
pubmed: 27146648
Eur Respir J. 2017 Aug 3;50(2):
pubmed: 28775050
Chest. 2012 Aug;142(2):448-456
pubmed: 22281797
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D42-50
pubmed: 24355641
Eur Respir J. 2018 Sep 16;52(3):
pubmed: 30002102
Pulm Circ. 2015 Sep;5(3):466-72
pubmed: 26401247
Eur Respir J. 2020 Nov 12;56(5):
pubmed: 32444411
Eur J Clin Nutr. 2020 Nov;74(11):1498-1513
pubmed: 31959942
JPEN J Parenter Enteral Nutr. 2019 Feb;43(2):181-193
pubmed: 30288759
Inflammopharmacology. 2019 Aug;27(4):649-661
pubmed: 31172335
Eur Respir J. 2009 May;33(5):1045-52
pubmed: 19129279
Clin Nutr ESPEN. 2019 Apr;30:159-169
pubmed: 30904217
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545968
J Biol Chem. 2017 Jun 16;292(24):10275-10287
pubmed: 28438835
J Clin Endocrinol Metab. 2013 Dec;98(12):4845-51
pubmed: 24037880
Physiol Rev. 2015 Jan;95(1):1-46
pubmed: 25540137
Int J Mol Sci. 2021 Feb 10;22(4):
pubmed: 33578743
Eur Respir J. 2015 Oct;46(4):903-75
pubmed: 26318161
J Am Med Dir Assoc. 2018 Jan;19(1):6-11.e3
pubmed: 28711425
Pulm Circ. 2020 Aug 21;10(3):2045894019885364
pubmed: 32913628
Front Physiol. 2018 May 31;9:641
pubmed: 29904352
Eur Respir J. 2011 Dec;38(6):1453-60
pubmed: 21478213
Eur J Clin Nutr. 2019 Feb;73(2):319-328
pubmed: 30367156
J Clin Pathol. 2013 Jul;66(7):620-2
pubmed: 23454726
Br J Nutr. 2003 May;89(5):552-72
pubmed: 12720576
Thorax. 2021 Dec;76(12):1209-1218
pubmed: 33963088
Sci Rep. 2018 Oct 9;8(1):15007
pubmed: 30302028
Am J Clin Nutr. 2006 Aug;84(2):419-26
pubmed: 16895893
Heart Fail Rev. 2018 Sep;23(5):711-722
pubmed: 29909553
Int Immunopharmacol. 2020 Nov;88:106934
pubmed: 32889242
Eur J Nutr. 2019 Dec;58(8):3121-3128
pubmed: 30523431
Respirology. 2018 Feb;23(2):148-159
pubmed: 28845582
PLoS One. 2017 Jul 7;12(7):e0180615
pubmed: 28686688
Chem Biol. 2014 Mar 20;21(3):319-29
pubmed: 24529992
J Nutr Sci. 2015 May 25;4:e23
pubmed: 26090099
Eur Respir Rev. 2017 Mar 29;26(143):
pubmed: 28356405
Eur Respir J. 2015 Aug;46(2):431-43
pubmed: 26113681
Am J Clin Nutr. 2016 Apr;103(4):1033-44
pubmed: 26864360